Cargando…

Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence

Background: Many pediatric inflammatory bowel disease (IBD) patients are now using biosimilars of anti-tumor necrosis factor-α (TNF-α), with increasing trends in recent years. This study reviewed all available data regarding the use of biosimilars in children with IBD. Methods: PubMed, Google Schola...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dipasquale, Valeria, Cicala, Giuseppe, Spina, Edoardo, Romano, Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970685/ https://www.ncbi.nlm.nih.gov/pubmed/35370732 http://dx.doi.org/10.3389/fphar.2022.846151

Ejemplares similares

A Narrative Review on Efficacy and Safety of Proton Pump Inhibitors in Children
por: Dipasquale, Valeria, et al.
Publicado: (2022)

Biosimilars in Pediatric IBD: Updated Considerations for Disease Management
por: Dipasquale, Valeria, et al.
Publicado: (2022)

Diet and Nutrition in Pediatric Inflammatory Bowel Diseases
por: Cucinotta, Ugo, et al.
Publicado: (2021)

Pancreatic Associated Manifestations in Pediatric Inflammatory Bowel Diseases
por: Cucinotta, Ugo, et al.
Publicado: (2021)

Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study
por: Wang, Fang, et al.
Publicado: (2023)

Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project
por: Barbieri, Maria Antonietta, et al.
Publicado: (2022)

The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors
por: Fabiani, Claudia, et al.
Publicado: (2019)

Enhanced Recovery Care versus Traditional Care after Surgery in Pediatric Patients with Inflammatory Bowel Disease: A Retrospective Case-Control Study
por: Dipasquale, Valeria, et al.
Publicado: (2022)

Switching Among Biosimilars: A Review of Clinical Evidence
por: Allocati, Eleonora, et al.
Publicado: (2022)

Challenges in paediatric inflammatory bowel diseases in the COVID-19 time
por: Dipasquale, Valeria, et al.
Publicado: (2020)

Nutrition in Pediatric Gastroenterology
por: Romano, Claudio, et al.
Publicado: (2021)

Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study
por: Massimi, Davide, et al.
Publicado: (2021)

Nocebo in Biosimilars and Generics in Neurology: A Systematic Review
por: Spanou, Ioanna, et al.
Publicado: (2019)

Biosimilars in paediatric inflammatory bowel disease
por: Sieczkowska-Golub, Joanna, et al.
Publicado: (2018)

A Systematic Review to Manage Avoidant/Restrictive Food Intake Disorders in Pediatric Gastroenterological Practice
por: Cucinotta, Ugo, et al.
Publicado: (2023)

Surgery-Related Quality of Life of Pediatric Patients With Crohn's Disease
por: Dipasquale, Valeria, et al.
Publicado: (2020)

Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel
por: Kanters, Tim A., et al.
Publicado: (2017)

Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review
por: Huang, Hui-Yao, et al.
Publicado: (2020)

Intensive Safety Monitoring of Rituximab (Biosimilar Novex(®) and the Innovator) in Pediatric Patients With Complex Diseases
por: Riva, Natalia, et al.
Publicado: (2022)

Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2022)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?
por: Baumgart, Daniel C., et al.
Publicado: (2019)

Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months
por: Argüelles-Arias, F., et al.
Publicado: (2017)

Gastrointestinal and nutritional care in pediatric neuromuscular disorders
por: Dipasquale, Valeria, et al.
Publicado: (2023)

Dysbiosis in the Pathogenesis of Pediatric Inflammatory Bowel Diseases
por: Comito, Donatella, et al.
Publicado: (2012)

Ototoxic Adverse Drug Reactions: A Disproportionality Analysis Using the Italian Spontaneous Reporting Database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2019)

Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers
por: Tursi, Antonio, et al.
Publicado: (2019)

Respiratory Tract Infections in Inflammatory Bowel Disease Patients Taking Vedolizumab: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Marafini, Irene, et al.
Publicado: (2021)

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
por: Husereau, Don, et al.
Publicado: (2018)

Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease
por: Huguet, Jose María, et al.
Publicado: (2021)

Current status of biosimilars in the treatment of inflammatory bowel diseases
por: Park, Dong Il
Publicado: (2016)

Insights on the use of biosimilars in the treatment of inflammatory bowel disease
por: Zheng, Michael K, et al.
Publicado: (2017)

Biosimilar biological drugs in the treatment of inflammatory bowel diseases
por: Kaniewska, Magdalena, et al.
Publicado: (2019)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease
por: Di Fusco, Davide, et al.
Publicado: (2019)

The Clinical Implications of Nocebo Effects for Biosimilar Therapy
por: Colloca, Luana, et al.
Publicado: (2019)

Editorial: Biological drugs and biosimilars in autoimmune diseases
por: Wajda, Anna, et al.
Publicado: (2023)

Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China
por: Wu, Qiyou, et al.
Publicado: (2023)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
por: Barbier, Liese, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7d8e2pi6dcnelv1ifgaiurm7ck